

I AM A BTS MEMBER

AUTHORS:

Julie De Beule

[Julie.debeule@kuleuven.be](mailto:Julie.debeule@kuleuven.be)

Steffen Fieuws

[steffen.fieuws@kuleuven.be](mailto:steffen.fieuws@kuleuven.be)

Diethard Monbaliu

[diethard.monbaliu@uzleuven.be](mailto:diethard.monbaliu@uzleuven.be)

M Naesens

[maarten.naesens@kuleuven.be](mailto:maarten.naesens@kuleuven.be)

M Sainz-Barriga

[mauricio.sainz@kuleuven.be](mailto:mauricio.sainz@kuleuven.be)

B Sprangers

[ben.sprangers@kuleuven.be](mailto:ben.sprangers@kuleuven.be)

D Kuypers,

[dirk.kuypers@uzleuven.be](mailto:dirk.kuypers@uzleuven.be)

J Pirenne

[jacques.pirenne@uzleuven.be](mailto:jacques.pirenne@uzleuven.be)

I Jochmans

[ina.jochmans@kuleuven.be](mailto:ina.jochmans@kuleuven.be)

**TITLE:** The effect of IGL-1 preservation solution on outcome after kidney transplantation: a retrospective single centre analysis

**ABSTRACT:**

**Background**

Institute George Lopez-1 (IGL-1) is a new preservation solution with unique features (low K<sup>+</sup>, low viscosity, PEG). Data on outcomes of IGL-1 preserved kidneys are scarce. We compared outcomes of IGL-1-preserved kidneys to those preserved with HTK or UW.

**Methods**

All deceased donor kidney transplantations performed at our centre (2000-2018), where IGL-1, HTK, or UW was used, were included. Multivariable analysis for delayed graft function (DGF), eGFR at 1y, and graft loss were performed. The risk of bias was reduced by using a double robust approach, consisting of propensity scored weighting and correction for confounders.

**Results**

1943 transplants were included. Unweighted incidence of DGF was 17% with IGL-1, 16% with UW, 25% with HTK. eGFR at 12 months was 46 (SE 1.6), 50 (0.6), and 50 (0.8) mL/min/1.73m<sup>2</sup>, respectively. Death-censored graft loss within 3 years was 7%, 9%, 7%, respectively. IGL-1 was not independently associated with any of the outcomes when compared to UW or HTK. Sensitivity analysis of transplants between 2010 and 2018 (n=917) showed similar results.

**Conclusion**

In this retrospective analysis, IGL-1 preservation seems to result in equal outcomes compared to UW, despite higher risk transplants in the IGL-1 group.

**Table**

DGF	OR (95% CI)	p-value
IGL vs HTK	1.05 (0.63;1.75)	0.99
IGL vs UW	1.38 (0.86;2.21)	0.25

  

Graft loss within 5 years	HR (95% CI)	
IGL vs HTK	0.65 (0.30;1.43)	0.59
IGL vs UW	0.95 (0.43;2.07)	0.99

  

eGFR at 1y	Mean diff (95% CI)	
IGL vs HTK	0.89 (-1.88;3.67)	0.99
IGL vs UW	-0.20 (-2.73;2.34)	0.99